Wed, Nov 26, 2014, 6:43 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Spectrum Pharmaceuticals, Inc. Message Board

baronm1234 11 posts  |  Last Activity: Nov 12, 2014 9:58 AM Member since: Dec 16, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    sppi balance sheet is not impressive

    by stocks.toshort Nov 11, 2014 10:16 PM
    baronm1234 baronm1234 Nov 12, 2014 9:58 AM Flag

    Ouch, I believe he is talking about Spectrum's current ratio which per the last 10Q was 2.1. He is obviously way out of his depth here as a current ratio of 2.1 in the pharma industry is very good.

  • Reply to

    Bitter Longs

    by imho_gfys_dyodd Oct 16, 2014 9:33 AM
    baronm1234 baronm1234 Oct 16, 2014 1:00 PM Flag

    kyelion, how dare you post with facts rather than misguided and delusional erroneous supposition. I am going to have to report you to yahoo and the sec. And before anyone misinterprets this post, it is said tongue and cheek in support of our valued poster kyelion.

  • Reply to

    Bitter Longs

    by imho_gfys_dyodd Oct 16, 2014 9:33 AM
    baronm1234 baronm1234 Oct 16, 2014 12:43 PM Flag

    I never said I hated management...I merely pointed out to you that us "bitter longs" do have the right to be upset with managements missteps. I won't argue with you anymore as you are obviously willing to say anything to change the context of your pathetic posts so as to not look foolish, which in turn makes you look even more foolish. Please just put me on ignore and I will do the same with you. With regard to your boorish post about the SEC investigations, sagent, generics, etc etc etc ...you sound ridiculous on those as well. I should have put you on ignore when you didn't know that $10 was not in the teens....my mistake.

  • Reply to

    Bitter Longs

    by imho_gfys_dyodd Oct 16, 2014 9:33 AM
    baronm1234 baronm1234 Oct 16, 2014 12:11 PM Flag

    If you love watching idiots implode on this board so much, buy a mirror. We are getting somewhere with you though now. You recognize that 10,11, and 12 are not teens...congratulations. Now read the rest of my post. " The only brief journey into the teens was precipitated by the removal of the bioscan requirement for the use of Zevalin and was clearly not revenue driven as you imply. " When was the bioscan requirement removed...Nov 18, 2011 just prior to the brief run up that occurred. It was CATALYST driven and not revenue driven. I was here as a long living it. So knock off the revisionist history....oh and by the way GFYS.

  • Reply to

    Bitter Longs

    by imho_gfys_dyodd Oct 16, 2014 9:33 AM
    baronm1234 baronm1234 Oct 16, 2014 11:54 AM Flag

    Above $10 is double digits not teens Einstein. Teens per the dictionary and every kindergartner and above in the free world is between 13 and 19. The only brief journey into the teens was precipitated by the removal of the bioscan requirement for the use of Zevalin and was clearly not revenue driven as you imply. Of course we were all led to believe by the company that the removal of the bioscan requirement was the last hurdle for Zevalin to become a blockbuster drug. Of course that was not the case as shown by Zevs $25-30M run rate. Get off your high horse, do your homework, try not to tell me that anything above $10 is teens (it makes you sound ridiculous) and finally, please don't tell me that my shares aren't worth less because of the mistakes that Raj and company made along the way.

  • Reply to

    Bitter Longs

    by imho_gfys_dyodd Oct 16, 2014 9:33 AM
    baronm1234 baronm1234 Oct 16, 2014 11:22 AM Flag

    No spin, no smear here except from you. I guess i just interpreted the sum total of your rubbish to be speaking of Fusilev. However, it makes no difference all products quarterly revs in the "teens" period averaged $64,500,000 and per the last Q report SPPI had revs of $46,800,000. I suppose next you are going to say that 46.8 is really the same as 64.5? I can not believe you are arrogant enough to double down on your own very easily disprovable BS.

  • Reply to

    Bitter Longs

    by imho_gfys_dyodd Oct 16, 2014 9:33 AM
    baronm1234 baronm1234 Oct 16, 2014 11:03 AM Flag

    " and the revenue is back to where it was when PPS was in teens". If you're trying to make a case at least do your homework. When SPPI was in the teens quarterly Fusilev rev's were $50,000,000 +. Total product sales including all drugs are now less than $50,000,000 per the last quarterly report and Fusilev is off by 50% from when SPPI was in the teens. Raj, his team, and the BOD screwed up with their statements and lack of supporting data...there is no sugar coating it. I am a frustrated long and it is maddening to hear revisionist history from from both pumpers and bashers.

  • Reply to

    SPI-2012 Go/No Go

    by tartiaboy Sep 4, 2014 11:54 AM
    baronm1234 baronm1234 Sep 4, 2014 12:51 PM Flag

    I think the Ligand CE Melphalan P III trial started in very early 2013 and we should see an NDA soon so who knows. But you are 100% correct that until we see trial design, it's all crystal ball stuff.

  • Reply to

    SPI-2012 Go/No Go

    by tartiaboy Sep 4, 2014 11:54 AM
    baronm1234 baronm1234 Sep 4, 2014 12:36 PM Flag

    I was hoping for more along the 12-18 month route. There is a significant population who could use the drug so I believe enrollment will happen faster than normal and I believe the results are measured relatively quickly with very simple bloodwork. Who knows, I've never been involved with a trial design, enrollment, etc, so my naive optimism may just be showing through.

  • Reply to

    Interpretation from Raj's Street interview....

    by ouch_yikes Sep 3, 2014 10:23 AM
    baronm1234 baronm1234 Sep 3, 2014 12:39 PM Flag

    My guess is CE Melph, which should become their best revenue producing drug very quickly upon approval. I think Apaz has taken a back seat to their other irons in the fire. It's disappointing given that I believe Apaz has great potential and was one of the reasons for my initial investment. I believe the original trial design set Apaz back at least 4 years because if it had been done multi installation, the blood in the bladder would not have been an issue on the 2nd install. Hind sight is 20/20 though.

  • baronm1234 baronm1234 Sep 3, 2014 12:34 PM Flag

    bluetick,
    I think in the context that it was said in, "blockbuster announcement" is referring to the go-no go on SPI-2012. The "blockbuster" being Spi-2012 and the "announcment" being the go no go.

    Sentiment: Strong Buy

SPPI
7.38+0.02(+0.27%)Nov 26 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.